{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T18:56:25Z","timestamp":1747162585930,"version":"3.40.5"},"reference-count":10,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["redjournal.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.ijrobp.2015.08.047","type":"journal-article","created":{"date-parts":[[2015,12,10]],"date-time":"2015-12-10T15:19:46Z","timestamp":1449760786000},"page":"210-211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["In Regard to Brachman et\u00a0al"],"prefix":"10.1016","volume":"94","author":[{"given":"Martin","family":"Brown","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6223-2961","authenticated-orcid":false,"given":"Eric","family":"Bernhard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Mitchel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Stone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2015.08.047_bib1","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.ijrobp.2014.12.050","article-title":"Phase 1\/2 trials of temozolomide, motexafin gadolinium, and 60-gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: Final results of RTOG 0513","volume":"91","author":"Brachman","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.08.047_bib2","doi-asserted-by":"crossref","first-page":"6610","DOI":"10.1073\/pnas.93.13.6610","article-title":"Gadolinium(III) texaphyrin: A tumor selective radiation sensitizer that is detectable by mri","volume":"93","author":"Young","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ijrobp.2015.08.047_bib3","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1200\/JCO.2003.12.122","article-title":"Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases","volume":"21","author":"Mehta","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2015.08.047_bib4","first-page":"86","article-title":"Re-evaluating gadolinium(III) texaphyrin as a radiosensitizing agent","volume":"60","author":"Bernhard","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2015.08.047_bib5","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/S0360-3016(02)02962-0","article-title":"Preliminary studies of the effects of gadolinium texaphyrin on the growth and radiosensitivity of EMT6 cells in\u00a0vitro","volume":"54","author":"Rockwell","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.08.047_bib6","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/j.ijrobp.2005.04.014","article-title":"Effects of motexafin gadolinium on DNA damage and X-ray\u2013induced DNA damage repair, as assessed by the comet assay","volume":"62","author":"Donnelly","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.08.047_bib7","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/S0360-3016(00)01566-2","article-title":"Effects of motexafin gadolinium on tumor metabolism and radiation sensitivity","volume":"49","author":"Xu","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.08.047_bib8","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0360-3016(01)01810-7","article-title":"Redox cycling by motexafin gadolinium enhances cellular response to ionizing radiation by forming reactive oxygen species","volume":"51","author":"Magda","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.08.047_bib9","doi-asserted-by":"crossref","first-page":"6089","DOI":"10.1158\/1078-0432.CCR-13-1116","article-title":"Lessons learned from radiation oncology clinical trials","volume":"19","author":"Liu","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2015.08.047_bib10","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1158\/2159-8290.CD-13-0452","article-title":"Oncology drug discovery: Planning a turnaround","volume":"4","author":"Toniatti","year":"2014","journal-title":"Cancer Discov"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301615032782?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301615032782?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T00:20:47Z","timestamp":1537143647000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301615032782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S0360301615032782"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2015.08.047","relation":{},"ISSN":["0360-3016"],"issn-type":[{"type":"print","value":"0360-3016"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In Regard to Brachman et\u00a0al","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2015.08.047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2014.12.050","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}